Thrivent Financial For Lutherans reduced its position in shares of Orthofix International N.V. (NASDAQ:OFIX) by 81.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,040 shares of the medical device company’s stock after selling 45,370 shares during the period. Thrivent Financial For Lutherans owned approximately 0.06% of Orthofix International N.V. worth $383,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP purchased a new stake in shares of Orthofix International N.V. during the first quarter worth about $20,021,000. Teachers Advisors LLC raised its stake in shares of Orthofix International N.V. by 676.2% in the first quarter. Teachers Advisors LLC now owns 276,340 shares of the medical device company’s stock worth $10,542,000 after buying an additional 240,740 shares during the last quarter. Norges Bank purchased a new stake in shares of Orthofix International N.V. during the fourth quarter worth about $5,664,000. Principal Financial Group Inc. purchased a new stake in shares of Orthofix International N.V. during the first quarter worth about $5,359,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Orthofix International N.V. by 122.5% in the first quarter. Bank of New York Mellon Corp now owns 242,068 shares of the medical device company’s stock worth $9,236,000 after buying an additional 133,281 shares during the last quarter. Hedge funds and other institutional investors own 97.31% of the company’s stock.

Orthofix International N.V. (NASDAQ:OFIX) traded up 1.18% during mid-day trading on Friday, hitting $48.00. The stock had a trading volume of 105,151 shares. Orthofix International N.V. has a one year low of $32.51 and a one year high of $49.60. The company has a market cap of $872.16 million, a price-to-earnings ratio of 112.41 and a beta of 0.25. The company has a 50 day moving average price of $45.91 and a 200-day moving average price of $41.33.

Orthofix International N.V. (NASDAQ:OFIX) last posted its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.01. The business had revenue of $108.90 million for the quarter, compared to analyst estimates of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.41 EPS. Equities analysts expect that Orthofix International N.V. will post $1.57 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/19/thrivent-financial-for-lutherans-decreases-position-in-orthofix-international-n-v-nasdaqofix-updated-updated-updated.html.

OFIX has been the topic of a number of research analyst reports. TheStreet raised Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th. BTIG Research initiated coverage on Orthofix International N.V. in a research report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 target price on the stock. Langenberg & Company reissued a “buy” rating and issued a $53.25 target price on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. Ladenburg Thalmann Financial Services began coverage on Orthofix International N.V. in a research report on Wednesday, June 14th. They issued a “buy” rating and a $53.25 target price on the stock. Finally, SunTrust Banks, Inc. began coverage on Orthofix International N.V. in a research report on Tuesday, May 23rd. They set a “buy” rating and a $49.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Orthofix International N.V. presently has an average rating of “Buy” and a consensus price target of $52.75.

In related news, insider Raymond Fujikawa sold 6,364 shares of Orthofix International N.V. stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $47.06, for a total transaction of $299,489.84. Following the transaction, the insider now owns 31,084 shares in the company, valued at approximately $1,462,813.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.60% of the company’s stock.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Institutional Ownership by Quarter for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.